Search results
Results From The WOW.Com Content Network
The Oxford–AstraZeneca COVID‑19 vaccine is used to provide protection against infection by the SARS-CoV-2 virus in order to prevent COVID-19 in adults aged 18 years and older. [1] The medicine is administered by two 0.5 ml (0.017 US fl oz) doses given by intramuscular injection into the deltoid muscle (upper arm).
The interim analysis was based on 468 cases of symptomatic COVID‑19 among 43,783 adult volunteers in Argentina, Brazil, Chile, Colombia, Mexico, Peru, South Africa, and the United States. No deaths related to COVID‑19 were reported in the vaccine group, while five deaths in the placebo group were related to COVID‑19. [118]
A COVID-19 vaccine card is a record often given to those who have received a COVID-19 vaccine showing information such as the date(s) one has received the shot(s) and the brand of vaccine one has received, sometimes including the lot number. The card also contains information identifying the recipient and the location where the shot was given.
The timeline of the COVID-19 pandemic lists the articles containing the chronology and epidemiology of SARS-CoV-2, [1] the virus that causes the coronavirus disease 2019 and is responsible for the COVID-19 pandemic. The first human cases of COVID-19 occurred in Wuhan, People's Republic of China, on or about 17 November 2019. [2]
For both the Oxford-AstraZeneca COVID-19 [46] and Gam-COVID-Vac vaccines the producer cells for the production of non-replicating adenoviral vectors were obtained from the HEK 293 cell line. [47] Each dose of Gam-COVID-Vac contains (1.0 ± 0.5) × 10 11 virus particles. [34]
SatuSehat (Indonesian for "one health"), formerly PeduliLindungi [1] (roughly "care to protect"), is a national integrated health data exchange platform, jointly developed by the Indonesian Ministry of Communication and Information Technology (Kemenkominfo), in partnership with Committee for COVID-19 Response and National Economic Recovery (KPCPEN), Ministry of Health (Kemenkes), Ministry of ...
The CureVac COVID-19 vaccine (abbreviated CVnCoV) was a COVID-19 vaccine candidate developed by CureVac N.V. and the Coalition for Epidemic Preparedness Innovations (CEPI). [2] The vaccine showed inadequate results in its Phase III trials with only 47% efficacy. [ 3 ]
By late November 2019, coronavirus disease 2019 had broken out in Wuhan, China. [2]As reported in Clinical Infectious Diseases on November 30, 2020, 7,389 blood samples collected between December 13, 2019, and January 17, 2020, by the American Red Cross from normal donors in nine states (California, Connecticut, Iowa, Massachusetts, Michigan, Oregon, Rhode Island, Washington and Wisconsin ...